Basal cell carcinoma screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Basal cell carcinoma}}
{{Basal cell carcinoma}}
{{CMG}} {{AE}} Saarah T. Alkhairy, M.D.
{{CMG}} {{AE}} Saarah T. Alkhairy, M.D.,{{M.N}}


==Overview==
==Overview==
Line 8: Line 8:
==Basal Carcinoma Screening==
==Basal Carcinoma Screening==
*The U.S Preventive Task Force has found no [[evidence]] to recommend for or against [[screening]]<ref>{{cite journal|title=Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement|journal=Annals of Internal Medicine|volume=150|issue=3|year=2009|pages=188|issn=0003-4819|doi=10.7326/0003-4819-150-3-200902030-00008}}</ref>.  
*The U.S Preventive Task Force has found no [[evidence]] to recommend for or against [[screening]]<ref>{{cite journal|title=Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement|journal=Annals of Internal Medicine|volume=150|issue=3|year=2009|pages=188|issn=0003-4819|doi=10.7326/0003-4819-150-3-200902030-00008}}</ref>.  
:*Task Force members state that “[[clinicians]] should remain [[alert]] for [[skin lesions]] with [[malignant]] [[Features (pattern recognition)|features]] noted in the context of [[Physical examination|physical examinations]] performed for other purposes,” and recognize that “even without formal [[screening]] programs, mortality from basal cell and [[squamous cell carcinoma]] is low compared with [[mortality]] from [[melanoma]], but early detection and treatment may reduce [[morbidity]] and disfigurement from these [[cancers]].”
:*Task Force members state that “[[clinicians]] should remain [[alert]] for [[skin lesions]] with [[malignant]] [[Features (pattern recognition)|features]] noted in the context of [[Physical examination|physical examinations]] performed for other purposes,” and recognize that “even without formal [[screening]] programs, [[mortality]] from basal cell and [[squamous cell carcinoma]] is low compared with [[mortality]] from [[melanoma]], but early detection and treatment may reduce [[morbidity]] and [[disfigurement]] from these [[cancers]].”
*The [[American Cancer Society]] recommends that a [[health care]] provider examine the [[skin]] every year if the [[patient]] is older than 40 years, and every 3 years if the [[patient]] is between 20-40 years
*The [[American Cancer Society]] recommends that a [[health care]] provider examine the [[skin]] every year if the [[patient]] is older than 40 years, and every 3 years if the [[patient]] is between 20-40 years


Line 15: Line 15:
{{Reflist|2}}
{{Reflist|2}}


[[Category:Disease]]
 
[[Category:Dermatology]]
[[Category:Up-To-Date]]
[[Category:Types of cancer]]
[[Category:Pathology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Surgery]]
[[Category:Surgery]]

Latest revision as of 15:04, 6 March 2019

Basal cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Basal Cell Carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Basal cell carcinoma screening On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Basal cell carcinoma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Basal cell carcinoma screening

CDC on Basal cell carcinoma screening

Basal cell carcinoma screening in the news

Blogs on Basal cell carcinoma screening

Directions to Hospitals Treating Basal cell carcinoma

Risk calculators and risk factors for Basal cell carcinoma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D., Maneesha Nandimandalam, M.B.B.S.[2]

Overview

The U.S. Preventive Services Task Force has found no evidence to recommend for or against screening. The American Cancer Society recommends that a health care provider examine the skin every year if the patient is older than 40 years, and every 3 years if the patient is between 20-40 years.

Basal Carcinoma Screening

References

  1. "Screening for Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. 150 (3): 188. 2009. doi:10.7326/0003-4819-150-3-200902030-00008. ISSN 0003-4819.